Teva Pharmaceutical Industries did not meet the primary endpoint of its Phase II trial to evaluate the efficacy, safety and tolerability of Talampanel, a drug that reduces disease-related functional deterioration in amyotrophic lateral sclerosis (ALS) patients.

The study results indicate the drug is safe but did not meet the efficacy requirements.

The double-blind, multicentre, multinational, randomised study was conducted in 25 sites across Canada, Israel, Europe and the US, involving 559 patients with ALS.

Also known as Lou Gehrig’s disease, ALS is a degenerative motor neuron disease that leads to paralysis and ultimately death within five years from the disease’s onset.

Over 10,000 patients every year are diagnosed with ALS in Europe and the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.